Quick counterattack on rival
|
|
- Annis Lamb
- 5 years ago
- Views:
Transcription
1 GILEAD SCIENCES - BUY Quick counterattack on rival This company was selected on the basis of Jyske Quant. Jyske Quant is a model that rates companies based on a string of factors. In that way, the model comes up with a total score that indicates whether the share is currently a good investment or not. This is an investment research report. This week Gilead signed an exclusive agreement with CVS Caremark about its hepatitis C treatment therapies, Sovaldi and Harvoni. Gilead has regained the majority of its price decline. Quick counterattack on rival: This week Gilead signed an exclusive agreement with CVS Caremark about its hepatitis C treatment therapies, Sovaldi and Harvoni. The agreement follows a similar agreement that AbbVie made for its recently approved hepatitis C-product. AbbVie's agreement with Express Script was, perhaps a bit too fast, seen as an attack on Gilead's 'monopoly' based on price dumping. There are now signs of a more varied picture of the events, and Gilead has regained most of its price decline, while AbbVie never increased after announcing its agreements. Hepatitis C treatment is not all about price: There are other and more important factors to consider than the price in relation to the right treatment of hepatitis C type 1 patients when choosing between Gilead's and AbbVie's products: 1. Gilead's Sovaldi hepatitis C therapy is trailblazing with a treatment Quant info Share information Quant score 5,9 Number of stocks (mill.) 159 Valuation 6,7 High/Low last 12 months 114/65 Valuation relative 5,1 Price movements 3/12 months -3%/38% Financial strength rate of between 94% and 99%. When it was launched at the end of 213, rival products only had a treatment rate of 5-8% and treatment processes were even very exhausting. Sovaldi triggered an accumulated treatment need due to its high success rate. Hence, Sovaldi will attain blockbuster status in its first full year and is expected to generate sales of around USD 11-12bn in 214. The price of Sovaldi is around USD 84, for a 12-week treatment. 5,4 - relative to index Quality 8,4 Market cap (mill. USD) Momentum 4,3 Free float 99% Performance 7,3 Avr. daily volume (mill.) 1584 Sector Fundamental valuation Risk News flow Health care Cheap High Positive 12-month target price 13, Current price 12,3 Reuters Bloomberg GILD.O GILD US Equity JB sec. code Pr ice tr end Gilead S&P 5 j f m a m j j a s o n d Source: Jyske Bank & Datastream Jyske Markets,Vestergade 8-16 DK-86 Silkeborg Senior Analyst, Equity Research, Robert Jakobsen jrj@jyskebank.dk Senior Analyst, Equity Research, Rune Dinesen rune.dinesen@jyskebank.dk This is an investment research. Important investor information: Please see the last pages of the report. 1
2 2. Gilead's new Harvoni therapy is based on the Sovaldi success with a much simpler therapy consisting of only one tablet a day in a 12-week treatment process with a list price of USD 94,5. However, Gilead has also announced that around half of the patients in the US may settle for an 8-week therapy, resulting in a further improved treatment process for the patient and a price that will fall to approx. USD 63,. 3. The price of AbbVie's product Viekira Pak is basically USD 83, before discount for a 12-week treatment with a treatment rate of around 96%. However, the Viekira Pak therapy requires that the patient takes between three and six pills per day, which is troublesome and may have an adverse effect on the treatment rate, as many patients are weak or old. In addition, Viekra Pak is prescribed as a 24-week therapy for some groups of patients. However, AbbView has promised Express Scripts not to demand payment for the extra need of drugs. AbbVie's new product does not seem to form the basis for such drastic changes in market share within hepatitis C as originally proclaimed. Obviously, this contributed to Gilead's price increases already before the CVS Caremark agreement this week. Comments from Express Scripts' management point to a reduction of the price towards the price level for patients in the EU countries, indicating a more rational price competition. In Germany, which is one of the largest EU markets for Sovaldi, the price of a treatment is around USD 7, against USD 84, in the US. CVS Caremark and Express Scripts are two of the leading US purchase/distribution companies (PBMs) which are acting on behalf of private individuals and public health care insurances. CVS and Express Scripts cover around 2% of the US owners of health care insurances. The intention is that CVS and Express Scripts must generate economies of scale for its customers, and they are, therefore, of course negotiating aggressively with the suppliers on the behalf of the customers. Other major PBMs include Prime Therapeutics and United Health. However, it should be considered whether exclusive agreements serve the patients best! Hepatitis C treatment will see competition over time; AbbVie was the first rival and around 217 Merck is expected to launch a therapy similar to Harvoni. In this connection we attach much importance to Gilead's market leadership based on having the first effective product (Sovaldi), the trackrecord in terms of treatment that is now established, and now also a simpler 'one pill per day' therapy (Harvoni). The AbbVie treatment is more cumbersome for the patient and will typically include a longer treatment process of between 12 and 24 weeks compared to 8 to 12 weeks for Gilead's Harvoni. 2
3 Please note that there are 11 different genotypes of hepatitis C. Type 1 is the most common one in the US and the EU. Sovaldi is approved as treatment of type 1, 2, 3, and 4. Harvoni is approved for type 1 and an application for approval of type 4 has been submitted. Viekira Pak is approved for type 1. Gilead focus on liver diseases: Liver diseases is one of the two major focus areas for Gilead, and the company has several NASH programmes under development. After Christmas Gilead purchased yet another NASH programme from a German company. NASH, or fat on the liver, may be the most widespread liver disease in the US and the UK and result in high health care costs. Gilead is expected to turn in its Q4 and 214 results on 4 February. Drugs that work: Gilead Sciences is a global market leader within HIV/AIDS and hepatitis C with new, better, and simpler 'one pill per day' therapies in large growing markets. Jyske Bank has a BUY recommendation for Gilead which has a high Jyske Quant score (5.9). Gilead has an attractive valuation with a large discount to peers and a price target of USD 13. For a biopharmaceutical company Gilead has a high risk profile. Gilead is trading at a significant discount to its rivals Peer Group Company P/E (214) P/E (215) P/B (214) P/B (215) EV/EBITDA (214) EV/EBITDA (215) Gilead Sciences Inc 13,1 1,5 7,4 4,8 9,8 8,6 Amgen Inc 18,3 17, 4,6 4,1 13,8 12,5 Celgene Corp 31,2 23,8 13,4 1,7 22, 18,4 Biogen Idec Inc 25,9 21,4 7,3 6, 17,1 15, Regeneron Pharmaceuticals Inc 4,5 34, 14,1 1,2 41,5 27,4 Merck & Co Inc 18, 17,9 3,5 3,6 12,1 11,6 Novartis AG 18,2 16,6 3, 2,9 15,9 15,4 Johnson & Johnson 17,9 17,3 3,9 3,5 11, 11, Pfizer Inc 14,5 14,7 2,8 2,8 9,2 9,5 Roche Holding AG 19,1 17,7 1, 8,6 12,8 12, Sanofi 15, 14,6 N/A N/A 1,9 1,5 Bristol-Myers Squibb Co 33,8 34,4 7,5 7,5 24,7 24,9 Weightet average 19,3 17,9 5,3 4,6 13,9 13, Mean 22,1 2, 7, 5,9 16,7 14,7 Premium compared with weighted avg. -32% -41% 39% 4% -3% -33% Source: Bloomberg 3
4 USD mio. USD Overview Gilead Company profile Gilead is a biopharmaceutical company with focus on research, development and commercialisation of drugs primarily within HIV/AIDS, hepatitis, oncology, respiratory, inflammation and cardiovascular diseases. Gilead is the market leader within HIV reporting annual sales of almost USD 1bn. In 211 Pharmasset was acquired, which made Gilead one of the market leaders within Hepatitis C (HCV) driven primarily by Sovaldi that was approved at the end of 213 and already in 214 is expected to deliver sales of USD 11.7bn. Oncology is the most recent focus area for Gilead, driven by Zydelig that is targeting chronic lymphocytic leukaemia. Gilead's pipeline is centred on making Gilead even stronger within HIV, hepatitis B and C, cancer and cardiovascular and respiratory diseases. Currently, Gilead has seven studies in phase III. In 215 Gilead's 6,1 employees are expected to generate sales of USD 29bn and an EBITDA result of USD 18.2bn. The company is headquartered in Sales growth and profitability Sales broken down by geographical area 4.77% 26.14% 15.48% Sales broken down by segment 4.64% 53.61% United States Europe Other international Worldwide - Other revenues 4.% 3.14% 4.83% Antiviral Products Letairis Ranexa AmBisome Royalte Revenue & Other Product 2.5 Fundamental valuation Revenue EPS (RS) Investment case The Jyske Quant score for Gilead is at the upper end of the Our BUY recommendation for Gilead is based on its leadership largest companies in the peer group. Particularly Gilead's within the treatment of HIV/AIDS and hepatitis C and a high Quality, Valuation and Price development scores are high. In Jyske Quant score. In addition to the market leadership within terms of key figures, Gilead is trading at a decent discount hepatitis C based on a high treatment success rate, the to its peer group with respect to P/E. Consensus also expects approval of Harvoni has also had the result that Gilead has the balance sheet to improve over the coming years based on now launched a treatment based on only one daily pill. Within significant sales growth. HIV/AIDS Gilead's product TAF is in the approval process and should be launched in the market before Gilead faces patent expirations within HIV/AIDS. TAF is also a treatment regime with only one pill which increases the treatment effect % Price triggers Risk factors Gilead obtains FDA and EMA approval of crucial drugs. Disappointing data from studies of crucial products. Gilead apply for new indications for existing products in the Gilead abandons the development of a crucial pipeline product. pipeline. Gilead does not obtain approval of new products. Sales potential of new drugs exceeds the consensus estimates. Gilead's efforts to obtain new indications fail. New health-care reforms have a positive impact on sales. New health-care reforms that have an adverse effect on sales Strong results and optimistic outlook. prices. New attractive acquisitions such as Pharmasset (was acquired Gilead is losing market share to its rivals. for USD 11bn) with an attractive/promising portfolio/pipeline. Unexpected negative side-effects of Gilead's drugs. Over the coming years a significant improvement of the balance Disappointing results and/or outlook comments. sheet is expected. This leaves scope for share buybacks and FX fluctuations (the company generates 4% of its sales dividend increases. outside the US). However, Gilead does not use hedging. 4
5 Important Investor Information (Disclaimer & Disclosure) Jyske Bank is supervised by the Danish Financial Supervisory Authority. The research report is based on information which Jyske Bank finds reliable, but Jyske Bank does not assume any responsibility for the correctness of the material nor any liability for transactions made on the basis of the information or the estimates of the report. The estimates and recommendations of the research report may be changed without notice. The research report is for the personal use of Jyske Bank's clients and may not be copied. This report is an investment research report. Conflicts of interest Jyske Bank has prepared procedures to prevent and preclude conflicts of interest thus ensuring that research reports are being prepared in an objective manner. These procedures have been incorporated in the business procedures covering the research activities of Jyske Markets, a business unit of Jyske Bank. Jyske Bank's analysts may not hold positions in the instruments for which they prepare research reports. If an analyst takes over for the responsible analyst in connection with illness, business activities, etc., this analyst cannot trade in the relevant instrument on the day of publication of the research report and the following day. Jyske Bank may, however, hold positions, have interests in or business relations with the instruments/companies for which such reports are prepared. Analysts receive no payment from persons interested in individual research reports. Company research reports have not been presented to the company prior to their release. Read more about Jyske Bank s policy on conflicts of interest at Jyske Bank s share recommendations current allocation Allocation of recommendations, Danish shares (number) Allocation of recommendations, all shares (number) Strong Buy Buy Reduce Sell Strong Buy Buy Reduce Sell Source: Jyske Bank Update of research report The planned update of the report will be prepared immediately upon the release of the company s financial statements. In addition, research reports may be prepared on special themes specifically for the company or research reports where the company is part of the special theme. These research reports are published on an ad-hoc basis. See the front page for the initial date of publication of the report. All prices stated are the latest closing prices before the release of the report, unless otherwise stated. Financial models Jyske Bank employs one or more of the following models: Discounted cash flow (free cash flow), Economic Value Added and the dividend model to determine the fundamental value of a company. The fundamental value is compared with a relative valuation based on multiples such as P/E and EV/EBITA. The recommendation and the price target are moreover adjusted for the expected news flow and the market sentiment based on knowledge of the industry and company-specific circumstances. Jyske Bank s recommendations take into account the expected development in the equity market, the various sectors and company-specific circumstances. 5
6 Risk Investment in this share is associated with risk. Movements in the equity market, the sector and/or news flows, etc. regarding the company may affect the price of the share. See the front page of the research report for our view of the risk associated with the share. The risk factors stated and/or calculations of sensitivities in the research report are not to be considered all-encompassing. If the share is traded in a currency other than the investor s base currency, the investor accepts an FX risk. In connection with an ADR or similar papers, the FX risk exists relative to the currency in which the underlying share trades. Ris k-adjus ted Recom m endation r etur n Strong b uy >2% Buy 1-2% R ed uce -1% Sell <% Source: Jyske Bank Recommendation concepts Our recommendations are relative to the market development and are based on an evaluation of the forecast return within the next twelve months. The forecast return is the difference between the current price and our 12-month price target (the price target includes the expected dividend). The equity market has historically yielded a return of around 1% (the US equity market, for instance, yielded a return of 1% during the period ). When we determine the recommendation for a share, we use the 1% as an estimate of the return in the equity market. Since our recommendations are relative and risk-adjusted, it is possible to compare our recommendations across sectors and risk categories. In addition, the potential is stated in absolute terms via our price target. It should be borne in mind, however, that the recommendation is the anchor. A BUY recommendation will remain a BUY recommendation until changed, even if price increases have taken the price too close to the price target. For clarification of the recommendation structure we refer to: The future and historical returns estimated in the research report are stated as returns before costs and tax-related circumstances since returns after costs and tax-related circumstances depend on a number of factors relating to individual client relations, custodian charges, volume of trade as well as market-, currency- and product-specific factors. It is not certain that the instrument will yield the stated expected future return/s. The stated expected future returns exclusively express our best assessment. Risk categorisation Green: An investment product type is in green category if the risk of losing all the invested amount is regarded as insignificant, and if the product type is simple to grasp. Amber: An investment product type is in amber category if there is a risk of losing the invested amount partially or fully, and if the product type is simple to grasp. Red: An investment product type is in red category if there is a risk of losing more than the invested amount, or if the product type is difficult to grasp. 6
Jyske Preferred, Senior Analyst, Equity Research Robert Jakobsen
Jyske Preferred, Jyske Preferred is a concentrated focus on the international stocks which the analysts assess as having the most attractive return potential. This week in Jyske Preferred you can read
More informationStrategic review in 2014 turned into execution
7.1.215 DANSKE BANK - STRONG BUY Strategic review in 214 turned into execution In connection with the annual report for 214, we expect that management will present specific initiatives in order to achieve
More information2016 targets already in the share price
GN STORE NORD - REDUCE 216 targets already in the share price This is a noncomplex product We reiterate our Reduce recommendation on GN Store Nord after the release of the Q3 13 results. With high expectations
More informationFocus on 2014 guidance, but share fully valued
2.2.214 ROCKWOOL - REDUCE Focus on 214 guidance, but share fully valued This is a noncomplex product We reiterate our Reduce recommendation ahead of the Q4 report as we believe the share is fully valued.
More informationGilead Sciences Announces Fourth Quarter and Full Year 2014 Financial Results
Gilead Sciences Announces Fourth Quarter and Full Year 2014 Financial Results February 3, 2015 4:07 PM ET - Fourth Quarter Product Sales of $7.2 billion, Up 137 percent Year over Year - - Full Year 2014
More informationWell on-track to deliver on our 2014 estimates
VESTAS - BUY Well on-track to deliver on our 2014 estimates This is a noncomplex product Vestas delivered very impressive Q4 13 results, confirming to us that it is well on track to return to normalized
More informationGrowth momentum picking up
WILLIAM DEMANT - BUY Growth momentum picking up This is a noncomplex product William Demant will report its full-year report on 27 February. We keep our Buy recommendation ahead of the report as we expect
More informationHealthcare Stocks The Stock Market SIM, Professor West. Yiping Yang, Lu Yu
Healthcare Stocks The Stock Market SIM, Professor West Yiping Yang, Lu Yu 1 Agenda Sector/SIM Overview Recommendation Summary Stock Analysis of Recommendations Vote 2 Sector Overview 3 Healthcare Sector
More informationJyske Preferred. BMW, China Mobile, J Sainsbury and Securitas remain on our list of preferred equities.
Jyske Preferred Jyske Preferred is a concentrated focus report on the international equities which, according to analysts, have the most attractive return potential. BMW, China Mobile, J Sainsbury and
More informationKey take aways from company day Case confirmed positioned for growth in the Nordics
DANSKE BANK - STRONG BUY Key take aways from company day Case confirmed positioned for growth in the Nordics Yesterday, Danske Bank made a presentation at our Company Day in Silkeborg confirming to us
More informationEarnings improvement. Dong Energy - BUY. But still loss due to impairment losses 5.5% Spread Price Source: Jyske Bank & Bloomberg
7-213 8-213 9-213 1-213 11-213 12-213 1-214 Dong Energy - BUY Earnings improvement This is a complex product But still loss due to impairment losses Dong Energy has this morning released its results for
More informationNew shareholders. Dong Energy - BUY. Higher than expected capital increase positive for DONG. Rating not likely to be changed in near future
Dong Energy - BUY New shareholders This is a complex product Higher than expected capital increase positive for DONG We maintain our BUY recommendation for DONG s issues following the news about an upcoming
More informationHealthcare Sector The Stock Market SIM, Professor West. Yiping Yang, Lu Yu
Healthcare Sector The Stock Market SIM, Professor West Yiping Yang, Lu Yu 1 Agenda Sector Overview Business and Economic Analysis Financial Analysis Valuation Analysis Recommendation 2 Sector Overview
More information43 YEARS OF PROFITS IN BULL & BEAR MARKETS OUTRAGEOUS DRUG PROFITS
43 YEARS OF PROFITS IN BULL & BEAR MARKETS OUTRAGEOUS DRUG PROFITS Outrageous Drug Profits By Jim Pearce and the team of analysts at Investing Daily It s hard to ignore an industry that will gross at least
More informationMeasuring the return from pharmaceutical innovation 2017 Methodology
Measuring the return from pharmaceutical innovation 2017 Methodology Contents Introduction 01 Methodology 02 Original cohort 03 Extension cohort 03 Assets evaluated 03 Methodology amendments and restatements
More informationRefresco changed to HOLD due to positive development
Refresco Refresco changed to HOLD due to positive development This is a case recommendation. The company will be included in our research universe as long as it holds price potential justifying a BUY recommendation.
More informationGilead Sciences Announces Fourth Quarter and Full Year 2013 Financial Results
Gilead Sciences Announces Fourth Quarter and Full Year 2013 Financial Results February 4, 2014 4:06 PM ET - Fourth Quarter Product Sales of $3.04 billion, Up 21 percent Year over Year - - Full Year 2013
More informationAbbVie Inc. NEUTRAL ZACKS CONSENSUS ESTIMATES (ABBV-NYSE) SUMMARY. Revenue Estimates (In millions of $) Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec)
February 10, 2015 AbbVie Inc. Current Recommendation NEUTRAL Prior Recommendation Outperform Date of Last Change 02/10/2015 Current Price (02/09/15) $55.48 Target Price $58.00 SUMMARY DATA (ABBV-NYSE)
More informationHealthcare - - SIM Company Presentations Lisa Liu Nadine Slezak Mark Venzor Rachel Wang
Healthcare - - SIM Company Presentations Lisa Liu Nadine Slezak Mark Venzor Rachel Wang Agenda Sector Overview SIM Portfolio Overview Additional Companies Assessed Stocks Recommendation Healthcare Sector:
More informationCOMPANY PRESENTATION - HEALTHCARE. Anthony Rogers, Thomas Rosol & Dylan Seymour
COMPANY PRESENTATION - HEALTHCARE Anthony Rogers, Thomas Rosol & Dylan Seymour Agenda Overview Business Analysis Financial Analysis Valuation Analysis Company Analysis Recommendation 2 S&P 500 Sector Weight
More informationTrailing PE Forward PE Buy 28 Analysts. 1-Year Return: -4.4% 5-Year Return: -1.0%
GILEAD SCIENCES INC (-O) Last Close 69.20 (USD) Avg Daily Vol 7.1M 52-Week High 89.54 Trailing PE 57.7 Annual Div 2.28 ROE 6.7% LTG Forecast -5.0% 1-Mo -9.3% November 16 NASDAQ Exchange Market Cap 89.5B
More informationNumericable to buy SFR
Numericable - HOLD Numericable to buy SFR This is a case recommendation. The company will be included in our research universe as long as it holds price potential justifying a BUY recommendation. Basically
More informationA Prescription for Investing in Health Care
A Prescription for Investing in Health Care HEALTH CARE SECTOR REPORT 23 October 2017 ANALYST(S) Linda D Bannister, CFA John Boylan, CFA Ashtyn Evans, CFA John Nako Buy-rated companies mentioned in this
More informationFrom Prescription to Patient: Navigating Barriers to HCV Treatment Initiation. Autumn Bagwell, PharmD, BCPS, AAHIVP Vanderbilt Specialty Pharmacy
From Prescription to Patient: Navigating Barriers to HCV Treatment Initiation Autumn Bagwell, PharmD, BCPS, AAHIVP Vanderbilt Specialty Pharmacy Objectives At the end of this presentation, the learner
More informationINTRINSIC VALUE ASSESSMENT OF GILEAD SCIENCES (GILD) Introduction. The Intrinsic Value of Gilead Sciences
JANUARY 1, 2018 This article was written with David J. Flood from The Investor s Podcast Introduction Gilead Sciences is an American based Biopharmaceutical corporation whose principal business involves
More informationINTERNATIONAL TRENDS SERIES
INTERNATIONAL TRENDS SERIES Issue 5: Private Payer Exclusivity Agreements June 8, 2015 Copyright 2015 by PDCI Market Access Inc. The information presented is property of PDCI Market Access. Unauthorized
More informationWhy Drugs Cost So Much
Page 1 of 5 Opinion OP-ED CONTRIBUTOR Why Drugs Cost So Much MARK PERNICE By PETER B. BACH JANUARY 14, 2015 ELI LILLY charges more than $13,000 a month for Cyramza, the newest drug to treat stomach cancer.
More informationInvestors Global Health Care Class
Interim Management Report of Fund Performance FOR THE SIX-MONTH PERIOD ENDED SEPTEMBER 3, 17 CAUTION REGARDING FORWARD-LOOKING STATEMENTS This report may contain forward-looking statements about the Fund,
More information(650) (650) GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS
CONTACTS: Investors Media Robin Washington Amy Flood (650) 522-5688 (650) 522-5643 For Immediate Release Sung Lee (650) 524-7792 GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS
More informationGilead Sciences Announces First Quarter 2011 Financial Results
Page 1 of 9 Gilead Sciences Announces First Quarter 2011 Financial Results - Product Sales of $1.86 Billion, Up 4 Percent over First Quarter 2010 - - Antiviral Product Sales of $1.63 Billion, Up 2 Percent
More informationRexam - we restate BUY
06-2007 01-2008 08-2008 03-2009 10-2009 05-2010 12-2010 07-2011 02-2012 09-2012 04-2013 14 November 2013 Rexam Rexam - we restate BUY This is a case recommendation. The company will be included in our
More informationFranklin Biotechnology Discovery Fund A (acc) USD
Franklin Discovery Fund A (acc) USD Franklin Templeton Investment Funds Fund Manager Report Equity Product Details 1 Fund Assets $2,125,578,204.37 Fund Inception Date 03/04/2000 Number of Issuers 93 Bloomberg
More informationInvestors: Gilead News Release. Gilead Sciences Announces Second Quarter 2010 Financial Results
Page 1 sur 7 Gilead Sciences Announces Second Quarter 2010 Financial Results - Total Revenues of $1.93 Billion, Up 17 Percent over Second Quarter 2009 - - Product Sales of $1.81 Billion, Up 15 Percent
More information$ Novo Nordisk A/S Sponsored ADR Class B. Grade 68.6
Grade Earnings Last Earnings Release 11/01/2017 Last Qtr. Actual vs. Est. $0.62 / $0.61 Next Release 11/02/2017 $0.61 Year Ending 12/31/2016 $2.17 Quick Facts Dividend Yield 1.48% 52 Wk High $55.04 52
More informationCIF Sector Recommendation Report (Spring 2013)
Date: 4/1/2013 Analyst: Jacob Allen CIF Sector Recommendation Report (Spring 2013) Sector: Healthcare Review Period: 3/13/2013 3/26/2013 Section (A) Sector Performance Review Copy/paste Sector Review Spreadsheet
More informationSummary of the financial reports for Gilead Sciences from
Summary of the financial reports for Gilead Sciences from 2010-2017 By David Belk MD First, some definitions: -Sales/revenue: For these reports I try to stick to the revenues from pharmaceutical sales
More informationGILD Gilead Sciences Inc. Sector: Healthcare HOLD
Analysts: Zachary Haller, Andrew Paley Brown and Sean Miller Washburn University Applied Portfolio Management GILD Sector: Healthcare HOLD Report Date: 4/18/2016 Market Cap (mm) $137,792 Annual Dividend
More informationGilead Sciences Announces Record Fourth Quarter and Full Year 2009 Financial Results
Gilead Sciences Announces Record Fourth Quarter and Full Year 2009 Financial Results - Full Year Total Revenues of $7.01 Billion, Up 31 Percent over 2008 -- Full Year Product Sales of $6.47 Billion, Up
More informationRaiffeisen HealthCare Equities
(Original German name: Raiffeisen-HealthCare-Aktien) Semi-annual fund report 2013 Table of contents General fund information... 3 Fund characteristics... 3 Legal notice... 4 Fund details... 5 Units in
More informationCIF Stock Recommendation Report (Spring 2014)
Date: 27 February 2014 Analyst Name: Hayden Wieck & Connor McCulloh CIF Stock Recommendation Report (Spring 2014) Company Name and Ticker: Bristol-Myers Squibb (BMY) Section (A) Investment Summary Recommendation
More informationNATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16
ISIN: INE987B01018 OCTOBER 15 th, 2015 STOCK DETAILS Sector NATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16 BSE Code 524816 Face Value 10.00 Pharmaceuticals 52wk. High / Low (Rs.) 2709.00/1245.40
More informationPage 1 of 8 Bristol-Myers Squibb Reports First Quarter 2013 Financial Results Posts First Quarter GAAP EPS of $0.37 and non-gaap EPS of $0.41 Net Sales were $3.8 Billion in the First Quarter Begins Commercial
More informationAbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results
PRESS RELEASE AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results Reports Full-Year Diluted EPS of $3.63 on a GAAP Basis; Adjusted Diluted EPS of $4.82, Reflecting Growth of 12.4 Percent
More informationFidelity Select Biotechnology Portfolio
QUARTERLY FUND REVIEW AS OF SEPTEMBER 30, 2017 Fidelity Select Portfolio Investment Approach Fidelity Select Portfolio is an industry-based, equity-focused strategy that seeks to outperform its benchmark
More informationPrice $98.43 (as of Apr 02, :00 PM ET)
GILD is in the S&P 500 S&P Capital IQ Recommendation S&P Capital IQ Equity Analyst Jeffrey Loo, CFA STRONG BUY Price $98.43 (as of Apr 02, 2015 4:00 PM ET) 12-Mo. Target Price $143.00 Report Currency USD
More informationH1 Results July 2012
H1 Results 2012 25 July 2012 Andrew Witty Chief Executive Officer Simon Dingemans Chief Financial Officer Continued execution of our strategy in a difficult external environment Grow a diversified global
More informationSECTOR PERFORMANCE REVIEW
SECTOR PERFORMANCE REVIEW Healthcare MELISSA CAMERON & WADE ROERSON A. Sector Performance Review A-1 Sector HC Review Period Start Date 1/12/2015 End Date 4/13/2015 Ticker Recommend CIF Current Beg. Stop-loss
More informationFranklin Biotechnology Discovery Fund A (acc) USD
Franklin Discovery Fund A (acc) USD Franklin Templeton Investment Funds Fund Manager Report Equity Product Details 1 Fund Assets $2,026,977,439.38 Fund Inception Date 03/04/2000 Number of Issuers 96 Bloomberg
More informationShort Cambrex Corporation
Short Cambrex Corporation NYSE:CBM Stephen Saroki O Brien Greene & Co. ssaroki@obriengreene.com Sohn Investment Conference April 2018 Introduction Investment Thesis 1. Cambrex is a smaller player in the
More informationThe Challenge of Drug Price Transparency
The Challenge of Drug Price Transparency Mason Tenaglia, VP Payer & Managed Care Insights December 2016 Copyright 2016 QuintilesIMS. All rights reserved. Why is there a call for price transparency? Commercial
More informationFactsheet: Deutsche Invest I CROCI Sectors Plus
Marketing Material Factsheet: Deutsche Invest I CROCI Sectors Plus Equity Funds - Sectors/Categories July 2018 As at 31/07/2018 Fund Data Investment Policy The sub-fund's assets are invested in shares
More informationMarket Capitalization $374.3 Billion
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUY BUY RATING SINCE 03/30/2012 TARGET PRICE $161.28 BUSINESS DESCRIPTION Johnson & Johnson, together with its subsidiaries,
More informationGilead Sciences Announces Record Third Quarter 2009 Financial Results
Gilead Sciences Announces Record Third Quarter 2009 Financial Results - Record Total Revenues of $1.80 Billion, Up 31 Percent over Third Quarter 2008 - - Record Product Sales of $1.65 Billion, Up 23 Percent
More informationWorking Capital to Sales
Pharmaceutical Industry Analysis April 2018 Excess Working Capital has risen 33% to 68 Billion since 2015 The first of these surveys came out in April 2012 and suggested that there was excess working capital
More informationJune Dear Fellow Takeda Shareholder,
June 2018 Dear Fellow Takeda Shareholder, Since joining Takeda in April 2014, my mission has been to continue the transformation of Takeda in order to ensure that Takeda will be a successful company in
More informationPutnam Global Health Care Fund
Putnam Global Health Care Fund Semiannual report 2 28 18 This global sector fund invests in stocks of health-care companies worldwide. FUND SYMBOL CLASS A PHSTX Putnam Global Health Care Fund Semiannual
More informationLigand to Acquire Metabasis for Cash and Contingent Value Rights
October 27, 2009 Ligand to Acquire Metabasis for Cash and Contingent Value Rights Ligand to Gain Fully Funded Partnership with Roche for Hepatitis and Promising Development-Stage Programs SAN DIEGO-- Ligand
More informationAcadia Pharmaceuticals. Daniel Berrios, Xianming Li, Ryan Matsumoto, Sunny Huang, Kojo Osei, Ariana Bhatia
Acadia Pharmaceuticals Daniel Berrios, Xianming Li, Ryan Matsumoto, Sunny Huang, Kojo Osei, Ariana Bhatia Introduction: ACAD Acadia Pharmaceuticals ACAD Small cap, relatively young, bio pharmaceutical
More informationSterling Pfizer Inc. Biotech Limited. 03 June 2009 Initiation Report. Wyeth acquisition to support Pfizer after losing patent for Lipitor RATING: BUY
Initiation Report Wyeth acquisition to support Pfizer after losing patent for Lipitor RATING: BUY Target price (6-24 month): US$18.76 Reuters ticker: PFE Bloomberg ticker: PFE US Analyst: Nishith Sanghvi
More informationPutnam Global Health Care Fund
Putnam Global Health Care Fund Annual report 8 31 17 This global sector fund invests in stocks of health-care companies worldwide. FUND SYMBOL CLASS A PHSTX Putnam Global Health Care Fund Annual report
More informationCWAG Prescription Drug Pricing Webinar
CWAG Prescription Drug Pricing Webinar January 9, 2018 Kipp Snider, J.D. Vice President, State Policy Pharmaceutical Research & Manufacturers of America (PhRMA) Medicines Are Expected to Account for a
More informationBackground Distribution and Safety Issues in the United States Consumer Advertising/Promotion World Health and Life Expectancy
CHAPTER ONE: EXECUTIVE SUMMARY Background Scope and Methodology Size and Growth of the Market Key Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION Background Distribution
More informationTreating epidemics with lowcost
Treating epidemics with lowcost generics Dr Andrew Hill Senior Visiting Research Fellow Pharmacology and Therapeutics, University of Liverpool, UK 1 Deaths per year (thousands) Global Burden of Disease
More informationA Payor and Provider s Perspective on Drug Pricing. Sharon Levine, MD Executive Vice President, The Permanente Federation
A Payor and Provider s Perspective on Drug Pricing Sharon Levine, MD Executive Vice President, The Permanente Federation National Academies of Sciences, Engineering and Medicine Stakeholder Meeting on
More informationINSTITUTIONAL RESEARCH Biotechnology COMPANY UPDATE Member FINRA/SIPC
INSTITUTIONAL RESEARCH Biotechnology COMPANY UPDATE Member FINRA/SIPC Toll Free: 561-391-5555 www.dawsonjames.com 1 North Federal Highway - Suite 500 Boca Raton, FL 33432 OncoSec Medical (Nasdaq/ONCS)
More informationThe Health Care Fortune Slide Series, Volume 57 February, 2018
The Health Care Fortune 500 5 Slide Series, Volume 57 February, 2018 1 Background Fortune groups companies into 21 sectors. This edition of the 5 Slide Series analyzes the 2017 health care sector Fortune
More informationFranklin Biotechnology Discovery Fund Advisor Class
Franklin Discovery Fund Advisor Class Equity Product Profile Product Details 1 Fund Assets $1,391,510,431.86 Fund Inception Date 09/15/1997 Number of Issuers 91 NASDAQ Symbol FTDZX Maximum Sales Charge
More informationIR Presentation template
1 MacroGenics, Inc. IR Presentation template Healthcare [SA, JA, sector] Sector Spring 2017 Senior Analyst: Austin Gasparini Junior Analysts: Donavon Young, Anuraag Gopaluni 2 Recommendation and Company
More informationOVERVIEW PROCESS SERVICES HARVONI. Simply on Your Side. Please see full Prescribing Information, including Patient Information.
HARVONI Simply on Your Side. OVERVIEW PROCESS SERVICES A breakthrough treatment with exceptional support Living with hepatitis C (Hep C) can come with a lot of uncertainty. But getting started with Hep
More informationPrescription Medicines: Costs in Context. Updated August 2016
Prescription Medicines: Costs in Context Updated August 2016 Medicines are Transforming the Treatment OF DEVASTATING DISEASES HEPATITIS C The leading cause of liver transplants and the reason liver cancer
More informationSpecialty Pharmacy: A Key to Organizational Success in Population Health Management
Specialty Pharmacy: A Key to Organizational Success in Population Health Management Scott Knoer, MS, PharmD, FASHP Chief Pharmacy Officer, Cleveland Clinic Steve Rough, MS, RPh, FASHP Director of Pharmacy,
More informationThe Biotech Growth Trust
The Biotech Growth Trust Positive outlook for the sector Investment trusts The Biotech Growth Trust (BIOG) aims to generate long-term capital growth from a concentrated portfolio of global companies. It
More information1 of 15 16/02/ :44. (
1 of 15 16/02/2015 10:44 (http://www.prnewswire.com/) 2 of 15 16/02/2015 10:44 - Reports Full-Year Adjusted EPS of $3.32, Up 5.7 Percent; GAAP EPS $1.10 - Delivers Fourth-Quarter Adjusted Revenue of $5.371
More informationFinancial view: A sustainable business model. Alan Hippe, CFO
Financial view: A sustainable business model Alan Hippe, CFO Capital allocation and R&D Continuous productivity improvements Focus on cash generation and allocation Solid margins with a high risk / high
More informationCorporate Valuation and Financial Strategy. Case Study The IPO of Mead Johnson Nutrition
FIN 673 Professor Robert B.H. Hauswald Corporate Valuation and Financial Strategy Kogod School of Business, AU Case Study The IPO of Mead Johnson Nutrition Continuing the refocusing of its activities on
More informationDiplomat.is/more. I m Jay.
Diplomat.is/more I m Jay. I have chronic lymphocytic leukemia. I m a retired submarine commander, a father, a husband, an avid woodcarver. I bike 20 miles a day. I know the Diplomat Difference. Investor
More informationMarket Capitalization $3.6 Billion. Weekly Price: (US$) SMA (50) SMA (100) 1 Year 2 Years
BUY HOLD SELL A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F Annual Dividend Rate BUSINESS DESCRIPTION Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of R-based
More informationCIF Sector Recommendation Report (Fall 2012)
CIF Sector Recommendation Report (Fall 2012) Date: March 3, 2013 Analyst: Nick Pascoe Sector: Healthcare Review Period: February 12 February 26 Section (A) Sector Performance Review Cougar Investment Fund
More informationWilliam Blair 35 th Annual Growth Stock Conference. June 9, 2015 NYSE: Q. Copyright 2014 Quintiles
William Blair 35 th Annual Growth Stock Conference June 9, 2015 Copyright 2014 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking
More informationDaewoong Pharmaceutical ( KS)
June 11, 214 (6962 KS) Shares and earnings touch bottom BUY (UPGRADE) Price (Jun. 1) W58,8 Target Price W74, % variance 25.9% KiDal Bae (82-2) 3772-1554 kdbae@shinhan.com EungHyun Kim (82-2) 3772-1568
More informationDISCLAIMER: Stock, forex, futures, and options trading is not appropriate for everyone. There is a substantial risk of loss associated with trading
DISCLAIMER: Stock, forex, futures, and options trading is not appropriate for everyone. There is a substantial risk of loss associated with trading these markets. Losses can and will occur. No system or
More informationCIF Sector Recommendation Report (Spring 2013)
Date: 24 April 2013 Analyst: Garrett Lachney CIF Sector Recommendation Report (Spring 2013) Sector: Healthcare Review Period: 04/05-04/18 Section (A) Sector Performance Review Copy/paste Sector Review
More informationFidelity Fund. Investment Approach QUARTERLY FUND REVIEW AS OF DECEMBER 31, 2017 FUND INFORMATION PERFORMANCE SUMMARY
QUARTERLY FUND REVIEW AS OF DECEMBER 31, 2017 Fidelity Fund Investment Approach Fidelity Fund is a diversified domestic equity strategy with a large-cap core orientation. Our guiding philosophy is that
More informationEQUITY RESEARCH. Reckitt Benckiser, French s Food business sold. Share Price: 7,936p Target Price: 8,000p* (+1%) 19 July 2017
Reckitt Benckiser, French s Food business sold Share Price: 7,936p Target Price: 8,000p* (+1%) Reckitt Benckiser (RB) has announced the sale of its French s Food business for US$ 4.2bn, which is ahead
More informationCIF Sector Update Report (Spring 2014)
CIF Sector Update Report (Spring 2014) Sector _Healthcare Analyst:_Connor_McCulloh Presentation Date:_4/7/2014 Review Period: Start Date: _March 20 th End Date: April 1 st Section (A) Sector Performance
More informationCOMPETITIVE POSITIONING OF THE TOP 10 PLAYERS GROWING ALLIANCES IN BIOPHARMACEUTICALS TABLE 7 KEY LICENSING AND PARTNERSHIP DEALS IN
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 2 INTENDED AUDIENCE... 3 METHODOLOGY AND INFORMATION SOURCES... 3 ANALYST CREDENTIALS...
More informationInvestors/Analysts Conference London/New York, February 2010 Ian Bishop
Investors/Analysts Conference London/New York, February 2010 Ian Bishop This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as
More informationBDH Industries Limited BSE Scrip Code:
BDH Industries Limited BSE Scrip Code: 524828 Pharmaceuticals October 23, 2012 Equity Statistics Current Market Price Rs. 16.95 52 Week High/Low Rs. 21.00/13.15 Market Capitalisation Rs. Crores 9.76 Free
More informationISHARES NASDAQ BIOTECHNOLOGY ETF (IBB)
ISHARES NASDAQ BIOTECHNOLOGY ETF (IBB) $109.44 USD Risk: High Zacks ETF Rank 2 - Buy Fund Type Issuer Benchmark Index Health Care ETFs BLACKROCK NASDAQ BIOTECHNOLOGY INDEX IBB Sector Weights Date of Inception
More informationBristol-Myers Squibb Reports Third Quarter 2014 Financial Results
Bristol-Myers Squibb Reports Third Quarter 2014 Financial Results Posts Third Quarter GAAP EPS of $0.43 and Non-GAAP EPS of $0.45 Achieves Significant Regulatory Milestones for PD-1 Inhibitor Opdivo Launches
More informationGLOBAL TRANSACTIONS FORECAST
2018 GLOBAL TRANSACTIONS FORECAST Healthcare A BAKER MCKENZIE SECTOR REPORT Deal activity to surge amid strong market conditions and US tax reform Uncertainty in the wake of Brexit, the US presidential
More informationBaxter International (NYSE: BAX) Industry: Health Care $4.31 $4.52 $4.86. Gross Margin 2012 est 51.5% PEG (Forward ) 1.51
Rating: BUY Price Target: $86.46 Close 11/14/2012 Price $65.04 Shares O/S (mm) 549.3 Outstanding (mm) Market Cap (bn) $35.73 Source: Google Finance Basic Information Beta.7 TEV/EBITDA 9.5 Trailing P/E
More informationDividend Builder Fund
Dividend Builder Fund Review of the 4 th Quarter 2017 For registered investment professional use only Contents 2 Introduction to fund Market performance Summary fund performance Performance drivers and
More informationCIF Sector Recommendation Report (Fall 2012)
CIF Sector Recommendation Report (Fall 2012) Date:4/3/2013 Analyst: Trevor Boren Sector: Healthcare Review Period: 3/20/2013 4/02/2013 Section (A) Sector Performance Review Review sector performance relative
More informationVeloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2016 and Provides Corporate Update
Corporate Release Copenhagen, Denmark, 24 August 2016 INTERIM REPORT FOR THE PERIOD 1 JANUARY TO 30 JUNE 2016 Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2016 and Provides
More informationJune Investor Presentation
June 2014 Investor Presentation Safe Harbor Certain statements included herein, including guidance and those that express management's objectives and the strategies to achieve those objectives, as well
More informationBlue Sky Grey Sky Analysis
Americas/United States Equity Research Biotechnology Research Analysts Alethia Young 212 538 0640 alethia.young@credit-suisse.com Eliana Merle 212 538 0678 eliana.merle@credit-suisse.com Grant Hesser 212
More informationTHE MONTHLY RESEARCH CONFERENCE CALL HEALTHCARE: SECTOR FUNDAMENTALS STILL HEALTHY ARGUS MODERATORS. Jim Kelleher, CFA Director of Research
TH MONTHLY RSARCH CONFRNC CALL HALTHCAR: SCTOR FUNDAMNTALS STILL HALTHY ARGUS MODRATORS Jim Kelleher, CFA Director of Research John M. ade President, Director of Portfolio Strategies David Toung Senior
More informationNote Important Disclosures on pages 5 and 6 Note Analyst Certification on page 5
COMPANY UPDATE / ESTIMATE CHANGE Key Metrics BMY - NYSE (as of 02/14/18) $65.35 Price Target N/A 52-Week Range $51.56 - $66.09 Shares Outstanding (mm) 1,645 Market Cap. ($mm) $106,689 1-Mo. Average Daily
More informationRisk: N/A Zacks ETF Rank N/A - BIB Sector Weights. Price Chart
November 24, 2016 PROSHARES ULTRA NASDAQ BIOTECHNOLOGY (BIB) $45.89 Risk: N/A Zacks ETF Rank N/A - Fund Type Issuer Healthcare - Biotech PROFUNDS GROUP BIB Sector Weights Benchmark Index NASDAQ BIOTECHNOLOGY
More information